[1] |
FU Weiran, ZOU Dongmei, NI Jing, SUN Wanling, GUO Yixian.
Short-Term Efficacy and Safety of Thiotepia-based Conditioning Regimen Combined with Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Primary Central Nervous System Lymphoma
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 664-668.
|
[2] |
ZHENG Kaifan, LENG Hongxu, XU Kaixuan, CAI Wenlu, ZHANG Ying, ZHAO Pengfei, TAN Shengjie, XIN Guizhong.
Research Progress on Intestinal Safety of Anthraquinone Laxatives
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 708-713.
|
[3] |
CHEN Huan, LIANG Jun, ZHAO Wei, XIA Qingrong.
Clinical Features and Risk Factors of Liver Injury Induced by Atypical Antipsychotic Drugs
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 410-414.
|
[4] |
DAI Biao, CAO Yin, SUN Yanhong, ZHANG Yuanyuan, XIA Qingrong.
808 Cases of Adverse Drug Reaction Caused by Antipsychotic Drugs
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 99-103.
|
[5] |
WANG Yuxi, ZHANG Zonglin, WANG Yingli, CHEN Yafei, LI Junsheng, HUO Yanfei, XIE Yanjun, LIU Wenqi.
560 cases of adverse drug reaction/event caused by Mailu Shutong pills
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 921-924.
|
[6] |
ZHAO Jun, DONG li, WANG Yang, LIANG Yu, YANG Xue, LI Enze.
Adverse reaction/event reports of esmolol
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 925-930.
|
[7] |
WU Tingxi, ZHAO Zhigang, SHI Yanfeng, ZHANG Yang, ZHANG Yinan, ZHU Bin.
Risk assessment of colchicine-associated neurological adverse events based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 341-345.
|
[8] |
PENG Miaoxin, WANG Yanqiong, XU Peipei, YANG Yonggong.
Analysis of epileptic seizures induced by lenalidomide with high-grade B cell lymphoma
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 585-587.
|
[9] |
LI Shuran, GUO Shanshan, CUI Xiaolan.
Research progress in correlations between herpes simplex virus-1 and Alzheimer's disease and in the prevention and treatment of herpes simplex virus-1 with traditional Chinese medicine
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 258-261.
|
[10] |
JIANG Kun, TANFeilong, WANG Zhongjuan, TAN Hongcheng, YOU Li’na.
One case of central nervous system toxicity induced by loratinib tablets
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1432-1434.
|
[11] |
PENG Jing, TUO Yali, LI Qiaoling, ZHOU Rong, LI Xinlin, PENG Hui.
Data analysis of adverse events of clobazam among children based on foreign pharmacovigilance safety spontaneous reporting system
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1264-1268.
|
[12] |
ZHANG Luxin, MENG Lu, ZHANG Hong.
Analysis of 327 reports of new adverse drug reactions
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1159-1162.
|
[13] |
ZHUANG Hongyan, ZANG Yannan, LIU Shanshan, NIU Mengxi, FANG Meng, YIN Dongqing, GUO Wei.
Analysis of neuropsychiatric adverse reactions caused by zolpidem
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 889-892.
|
[14] |
CHEN Fangfang, ZHANG Hongxu.
Pharmacy practice during the treatment of primary central nervous system lymphoma with high dose methotrexate
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 446-449.
|
[15] |
CAO Lisha, WANG Jisheng, ZHANG Fang, CHEN Jing, GUO Haoning.
Adverse drug reactions caused by antipsychotic drugs in 631 cases
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 322-324.
|